U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H24N2O4
Molecular Weight 428.4798
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of A-922500

SMILES

OC(=O)[C@@H]1CCC[C@H]1C(=O)C2=CC=C(C=C2)C3=CC=C(NC(=O)NC4=CC=CC=C4)C=C3

InChI

InChIKey=BOZRFEQDOFSZBV-DHIUTWEWSA-N
InChI=1S/C26H24N2O4/c29-24(22-7-4-8-23(22)25(30)31)19-11-9-17(10-12-19)18-13-15-21(16-14-18)28-26(32)27-20-5-2-1-3-6-20/h1-3,5-6,9-16,22-23H,4,7-8H2,(H,30,31)(H2,27,28,32)/t22-,23-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H24N2O4
Molecular Weight 428.4798
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18183944

A-922500 is a potent, selective, and orally bioavailable DGAT-1 inhibitor. A-922500 confers weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depletes serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice. A-922500 (0.03, 0.3 and 3 mg/kg, p.o.) dose-dependently attenuates the maximal postprandial rise in serum triglyceride concentrations. DGAT-1 inhibition by A-922500 can be a novel therapeutic approach to the treatment of hypertriglyceridemia in humans.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Zucker fatty rats and diet-induced dyslipidemic hamsters were dosed orally with A-922500 (0.03, 0.3, and 3-mg/kg) for 14 days. Serum triglycerides were significantly reduced by the 3 mg/kg dose
Route of Administration: Oral
A922500 inhibits human recombinant DGAT1 expressed in Sf9 cells with IC50 of 7 nM
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:57:40 GMT 2023
Edited
by admin
on Sat Dec 16 10:57:40 GMT 2023
Record UNII
44698M475X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
A-922500
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 2-((4'-(((PHENYLAMINO)CARBONYL)AMINO)(1,1'-BIPHENYL)-4-YL)CARBONYL)-, (1R,2R)-
Systematic Name English
Code System Code Type Description
CAS
959122-11-3
Created by admin on Sat Dec 16 10:57:40 GMT 2023 , Edited by admin on Sat Dec 16 10:57:40 GMT 2023
PRIMARY
PUBCHEM
24768261
Created by admin on Sat Dec 16 10:57:40 GMT 2023 , Edited by admin on Sat Dec 16 10:57:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID80242027
Created by admin on Sat Dec 16 10:57:40 GMT 2023 , Edited by admin on Sat Dec 16 10:57:40 GMT 2023
PRIMARY
FDA UNII
44698M475X
Created by admin on Sat Dec 16 10:57:40 GMT 2023 , Edited by admin on Sat Dec 16 10:57:40 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY